ecancermedicalscience

Short Communication

Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

10 Dec 2008
P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LB Silverman

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (¡Ý20¨C30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

Article metrics: 1847 views
316
1531

Related Articles

Marianna Masiero, Derna Busacchio, Paolo Guiddi, Paola Arnaboldi, Gennaro Musi, Ottavio De Cobelli, Florence Didier, Gabriella Pravettoni
Maria Asunción Algarra, Maria José Juan Fita, Sergio Sandiego, Héctor Augusto Aguilar, Pablo Álvarez, Mateo Quispe, Antonio Salvador, Adoración Egido, Javier Lavernia, Isidro Machado, José Rubio Briones, Miguel Ángel Climent
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco
Lekha Madhavan Nair, KM Jagathnath Krishna, Aswin Kumar, Susan Mathews, John Joseph, Francis Vadakkumparambil James